Compare T Rowe Price Group Inc (TROW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs 10X Genomics Inc — how do they compare? T Rowe Price Group Inc trades at $104.25 (market cap $22.20B), while 10X Genomics Inc trades at $79.3 (market cap $9.92B). The key difference: T Rowe Price Group Inc is far larger — about 2.2× 10X Genomics Inc's market cap, and T Rowe Price Group Inc pays a 5% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold T Rowe Price Group Inc for 115 Days and 10X Genomics Inc for 92 Days on average.
| TROW | TXG | |
|---|---|---|
Market Cap | $22.20B | $9.92B |
Volume | 1,738,431 | 9,372,166 |
Sector | Financials | Health |
52-Week High | $121.68 | $97.74 |
52-Week Low | $86.19 | $11.48 |
Typical Hold Time | 115 Days | 92 Days |
Enterprise Value | $19.39B | $9.44B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $104.23, up 0.61% with bearish technical signals but strong fundamentals including a 29.26% net margin and $2.09B net income. The stock shows consistent earnings beats and dividend growth, supported by $1.90 trillion in assets under management as of August 2026. Recent news highlights dividend sustainability and ETF expansion through acquisitions.
Outlook remains positive with a $112 consensus price target offering 7.5% upside, though technical weakness and market volatility pose near-term risks. The company's 40-year dividend growth history and expanding product portfolio provide stability, while net outflows and competitive pressures require monitoring for long-term investors.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
